KalVista Pharmaceuticals Reports Fiscal First Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
KalVista Pharmaceuticals (KALV) Reports Q1 Loss of $0.47/Share
September 14, 2018 7:33 AM EDTKalVista Pharmaceuticals (NASDAQ: KALV) reported Q1 EPS of ($0.47), versus ($0.51) reported last year. Revenue for the quarter came in at $3.7 million, versus $10 thousand reported last year.
For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.
... More